Gland Pharma Shares Surge 16% to Record High Following Strong Q4 Results
Gland Pharma shares jump 16% to 52-week high on Q4; analysts retain 'Buy'
Image: Business Standard
Gland Pharma's shares rose 16.22% to a 52-week high of ₹2,170 following impressive Q4 results for FY26, where profit nearly doubled and revenue increased by 22%. Analysts from Elara Capital and Motilal Oswal Financial Services maintained 'Buy' ratings, citing strong growth momentum and product launches.
- 01Gland Pharma's adjusted profit after tax (APAT) for Q4FY26 reached ₹366.7 crore, a 97% increase from ₹186.5 crore in Q4FY25.
- 02Revenue from operations rose 22% year-on-year to ₹1,742.8 crore in Q4FY26.
- 03The company announced a final dividend of ₹20 per equity share for FY26, pending shareholder approval.
- 04Elara Capital raised its target price for Gland Pharma to ₹2,306, indicating a potential upside of 6.3%.
- 05Motilal Oswal Financial Services set a target price of ₹2,300, forecasting a 19% earnings CAGR over FY26-28.
Advertisement
In-Article Ad
Shares of Gland Pharma surged 16.22% to a 52-week high of ₹2,170 on May 18, following the announcement of strong financial results for the fourth quarter and fiscal year ending March 31, 2026. The company's adjusted profit after tax (APAT) nearly doubled to ₹366.7 crore, reflecting a 97% year-on-year increase, while revenue rose 22% to ₹1,742.8 crore. Analysts from Elara Capital and Motilal Oswal Financial Services reaffirmed their 'Buy' ratings, citing robust earnings and growth potential from new product launches. Elara Capital raised its target price to ₹2,306, indicating a 6.3% upside, while Motilal Oswal set a target of ₹2,300, projecting a 19% earnings CAGR driven by a strong product pipeline and improved profitability. The board has also recommended a final dividend of ₹20 per equity share for FY26, pending approval at the upcoming Annual General Meeting.
Advertisement
In-Article Ad
The surge in Gland Pharma's share price may enhance investor confidence and attract more capital to the pharmaceutical sector, benefiting stakeholders.
Advertisement
In-Article Ad
Reader Poll
Do you believe Gland Pharma will maintain its growth momentum in the coming quarters?
Connecting to poll...
More about Gland Pharma
Nifty Index Declines Amid Global Weakness and Consumer Durables Slide
Business Standard • May 18, 2026
Gland Pharma Shares Surge 16% to Record High Amid Market Turmoil: Investment Insights
Mint • May 18, 2026
Gland Pharma Reports 97% Surge in Q4 Profit, Driving Stock Up 12.37%
Business Standard • May 18, 2026
Read the original article
Visit the source for the complete story.